Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.
One of the newest agents used in the treatment of breast cancer is trastuzumab (Herceptin), a new recombinant DNA-derived humanized monoclonal antibody against the proto-oncogene, HER-2/neu gene product. However, despite its proven clinical efficacy, serious adverse effects leading to trastuzumab-induced cardiomyopathy have been described in up to 27% of patients receiving combination therapy with anthracyclines. There has been little published on the clinical syndrome of trastuzumab-induced cardiomyopathy. We describe three cases, of both reversible and irreversible cardiomyopathy, associated with the use of this novel and effective agent in HER-2 overexpressing breast cancer.
Tham
Yee-Lu
YL
Breast Center at Baylor College of Medicine, Houston, TX 77030, USA.
Verani
Mario S
MS
Chang
Jenny
J
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D000090063:Proto-Oncogene Mas; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D000068878:Trastuzumab